busulfan has been researched along with Thrombotic Microangiopathies in 2 studies
Thrombotic Microangiopathies: Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination tacrolimus and sirolimus graft-versus-host disease (GVHD) prophylaxis for allogeneic transplant in patients conditioned with a fractionated total body irradiation-based regimen has shown encouraging results." | 5.14 | A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. ( Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D, 2010) |
| "Only viral infections were significantly increased in the non-TBI group." | 1.48 | Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. ( Anagnostopoulos, A; Apostolou, C; Athanasiadou, A; Batsis, I; Bousiou, Z; Bouziana, S; Chatziioannou, K; Constantinou, V; Douka, V; Gavriilaki, E; Gianouzakos, V; Iskas, M; Lalayanni, C; Mallouri, D; Papathanasiou, M; Sakellari, I; Sotiropoulos, D; Yannaki, E, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakellari, I | 1 |
| Gavriilaki, E | 1 |
| Chatziioannou, K | 1 |
| Papathanasiou, M | 1 |
| Mallouri, D | 1 |
| Batsis, I | 1 |
| Bousiou, Z | 1 |
| Bouziana, S | 1 |
| Constantinou, V | 1 |
| Douka, V | 1 |
| Apostolou, C | 1 |
| Iskas, M | 1 |
| Lalayanni, C | 1 |
| Athanasiadou, A | 1 |
| Sotiropoulos, D | 1 |
| Yannaki, E | 1 |
| Gianouzakos, V | 1 |
| Anagnostopoulos, A | 1 |
| Rodriguez, R | 1 |
| Nakamura, R | 1 |
| Palmer, JM | 1 |
| Parker, P | 1 |
| Shayani, S | 1 |
| Nademanee, A | 1 |
| Snyder, D | 1 |
| Pullarkat, V | 1 |
| Kogut, N | 1 |
| Rosenthal, J | 1 |
| Smith, E | 1 |
| Karanes, C | 1 |
| O'Donnell, M | 1 |
| Krishnan, AY | 1 |
| Senitzer, D | 1 |
| Forman, SJ | 1 |
1 trial available for busulfan and Thrombotic Microangiopathies
| Article | Year |
|---|---|
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hema | 2010 |
1 other study available for busulfan and Thrombotic Microangiopathies
| Article | Year |
|---|---|
Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
Topics: Adult; Age Factors; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Gr | 2018 |